首页> 外文期刊>Bone marrow transplantation >Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation
【24h】

Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation

机译:回顾性队列研究比较单脐带血移植术后静脉内鸟类与总体辐射的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Limited to inadequate stem-cell doses, cord blood transplantation (UCBT) is accompanied by increased graft failure and delayed haematopoietic recovery. The conditioning regimen is critically important for engraftment, and numerous trials have been undertaken comparing the outcomes of IV Bu and TBI, but there are no comparative data for UCBT. We conducted a retrospective multicentre study to analyse the outcomes of IV Bu and TBI in UCBT patients with haematologic malignancies. Between 1 May, 2008 and 31 Mar, 31 2018, a total of 331 patients from the China Umbilical Cord Blood Transplantation Corporation (IV Bu, n = 131; TBI, n = 200) were evaluated. The cumulative incidence of neutrophil engraftment was 91.6% in the IV Bu/Cy cohort and 98.0% in the Cy/TBI cohort (P < 0.001). The median times to neutrophil engraftment were 16 and 19 days (P < 0.001), respectively. Multivariate analysis showed no statistical difference for nonrelapse mortality (hazard ratio [HR], 1.11; 95% confidence interval [CI], 0.66 to 1.86; P = 0.695), relapse (HR, 0.90; 95% CI, 0.50 to 1.60; P = 0.713) and overall survival (HR, 0.94; 95% CI, 0.61 to 1.44; P = 0.763) between the two conditioning regimens. Our results show that both IV Bu and TBI are valid myeloablative conditioning regimens for haematologic malignancy patients treated with UCBT.
机译:限于干细胞剂量不足,脐带血移植(UCBT)伴随着增加的接枝衰竭和延迟出血恢复。调理方案对于植入至关重要,已经进行了众多试验,比较了IV Bu和TBI的结果,但没有对UCBT的比较数据。我们进行了回顾性的多期面研究,分析了患有血栓药物恶性肿瘤患者的IV BU和TBI的结果。 2008年5月1日至3月31日至3月31日至2018年3月31日,评估了中国脐带血移植公司(IV,N = 131; TBI,N = 200)共331名患者。中性粒细胞植入的累积发病率为91.6%在IV / TBI队列中的98.0%(P <0.001)。中性粒细胞植入的中位数分别为16至19天(P <0.001)。多变量分析显示非筛选死亡率的统计学差异(危害比[HR],1.11; 95%置信区间[CI],0.66至1.86; P = 0.695),复发(HR,0.90; 95%CI,0.50至1.60; P.在两个调理方案之间,总存活(HR,0.94; 95%CI,0.61至1.44; p = 0.763)。我们的研究结果表明,IV BU和TBI都是用UCBT处理的血液学恶性肿瘤患者的有效髓鞘调节方案。

著录项

  • 来源
    《Bone marrow transplantation》 |2019年第10期|共11页
  • 作者单位

    Shandong Univ Sch Med Jinan Shandong Peoples R China;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Shanghai Jiao Tong Univ Sch Med Xinhua Hosp Dept Haematol Shanghai Peoples R China;

    Wannan Med Coll Affiliated Hosp 1 Dept Haematol Wuhu Peoples R China;

    Sun Yat Sen Univ Dept Haematol Guangzhou Guangdong Peoples R China;

    Fujian Med Univ Union Hosp Dept Haematol Fuzhou Fujian Peoples R China;

    Jilin Univ Hosp 1 Dept Haematol Changchun Jilin Peoples R China;

    Chenzhou 1 Peoples Hosp Dept Haematol Chenzhou Peoples R China;

    Anhui Med Univ Inst Haematol Hefei Anhui Peoples R China;

    Anhui Med Univ Inst Haematol Hefei Anhui Peoples R China;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Shandong Univ Sch Med Jinan Shandong Peoples R China;

    Shandong Univ Sch Med Jinan Shandong Peoples R China;

    Shandong Univ Sch Med Jinan Shandong Peoples R China;

    Shandong Univ Sch Med Jinan Shandong Peoples R China;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Wannan Med Coll Affiliated Hosp 1 Dept Haematol Wuhu Peoples R China;

    Jilin Univ Hosp 1 Dept Haematol Changchun Jilin Peoples R China;

    Univ Sci &

    Technol China Div Life Sci &

    Med Affiliated Hosp 1 USTC Dept Haematol Hefei Anhui;

    Shandong Univ Sch Med Jinan Shandong Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号